Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 247 articles:
HTML format
Text format



Single Articles


    August 2018
  1. MURRAY KF, Balistreri WF, Bansal S, Whitworth S, et al
    Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123.
    PubMed     Text format     Abstract available


  2. GANE EJ, Stedman CA, Schwabe C, Vijgen L, et al
    Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30126.
    PubMed     Text format     Abstract available


  3. REFOLO G, Ciccosanti F, Di Rienzo M, Perdomo AB, et al
    Negative regulation of MAVS-mediated antiviral signaling by the mitochondrial protein LRPPRC during HCV infection.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30149.
    PubMed     Text format     Abstract available


  4. HUSSAINI T, Krajden M, Mitchell RA, Yoshida EM, et al
    Transplanting Hepatitis C seropositive, nucleic acid test negative donor organs into hepatitis C negative recipients.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30121.
    PubMed     Text format     Abstract available


    July 2018
  5. GOLDEN-MASON L, Rosen HR
    Revisiting the Paradox of ISG expression as a predictor of HCV treatment response, a decade later.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30195.
    PubMed     Text format     Abstract available


  6. JAIN MK, Thamer M, Therapondos G, Shiffman ML, et al
    Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30171.
    PubMed     Text format     Abstract available


  7. TUCCI F, Calbi V, Barzaghi F, Migliavacca M, et al
    Successful treatment with Harvoni((R)) in an ADA-SCID infant with HCV infection allowed gene therapy with Strimvelis((R)).
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30160.
    PubMed     Text format     Abstract available


    June 2018
  8. MARTINS PN
    Transplantation of Livers from Viremic HCV Positive Donors into HCV Negative Recipients.
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30106.
    PubMed     Text format    


    May 2018
  9. COURI T, Gupta T, Weyer G, Aronsohn A, et al
    Pay It Forward: Building Capacity to Treat Hepatitis C by Training Our Own Residents.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30101.
    PubMed     Text format    


  10. SALAM KA, Wang RY, Grandinetti T, De Giorgi V, et al
    Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30087.
    PubMed     Text format     Abstract available


  11. ZHANG H, Zhang C, Tang H, Gao S, et al
    CD2-associated Protein Contributes to Hepatitis C Virus Propagation and Steatosis by Disrupting Insulin Signaling.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30073.
    PubMed     Text format     Abstract available


    April 2018
  12. ALAO H, Cam M, Keembiyehetty C, Zhang F, et al
    Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During DAA Therapy.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.29921.
    PubMed     Text format     Abstract available


  13. CHOLANKERIL G, Gadiparthi C, Kim D, Ahmed A, et al
    Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30043.
    PubMed     Text format    


  14. TERRAULT NA
    Hepatitis C in Patients with Renal Disease: A Deeper Dive into the KDIGO Guideline.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30047.
    PubMed     Text format    


  15. REAU N, Kwo PY, Rhee S, Brown RS Jr., et al
    Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046.
    PubMed     Text format     Abstract available


  16. CHHATWAL J, Bethea ED, Samur S, Chung RT, et al
    Reply to Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30042.
    PubMed     Text format    


  17. ALLAIRE M, Nahon P, Layese R, Bourcier V, et al
    Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034.
    PubMed     Text format     Abstract available


  18. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Text format     Abstract available


  19. HOUSSEL-DEBRY P, Coilly A, Fougerou-Leurent C, Jezequel C, et al
    12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29918.
    PubMed     Text format     Abstract available


    March 2018
  20. FAILLACI F, Marzi L, Critelli R, Milosa F, et al
    Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29911.
    PubMed     Text format     Abstract available


  21. RAMAMURTHY N, Marchi E, Ansari MA, Pedergnana V, et al
    Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877.
    PubMed     Text format     Abstract available


    February 2018
  22. FOSTER GR, Agarwal K, Cramp ME, Moreea S, et al
    Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
    Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.
    PubMed     Text format     Abstract available


  23. KWON YC, Meyer K, Peng G, Chatterjee S, et al
    Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29843.
    PubMed     Text format     Abstract available


  24. DOI A, Hikita H, Sakamori R, Tahata Y, et al
    NS5A-P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29836.
    PubMed     Text format    


  25. SMITH D, Magri A, Bonsall D, Ip CL, et al
    Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29837.
    PubMed     Text format     Abstract available


    January 2018
  26. BERENGUER J, Gil-Martin A, Jarrin I, Moreno A, et al
    All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29814.
    PubMed     Text format     Abstract available


  27. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Response to Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29770.
    PubMed     Text format    


  28. CONGLY SE, Lee SS
    Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29771.
    PubMed     Text format    


  29. HERRMANN E, de Ledinghen V, Cassinotto C, Chu WC, et al
    Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.
    Hepatology. 2018;67:260-272.
    PubMed     Text format     Abstract available


    December 2017
  30. GRAKOUI A, Walker CM
    Of mice, rats and men: Small animal model of hepatitis C virus infection.
    Hepatology. 2017 Dec 27. doi: 10.1002/hep.29765.
    PubMed     Text format    


  31. GARCIA-TSAO G
    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    PubMed     Text format    


  32. CHHATWAL J, Samur S, Bethea ED, Ayer T, et al
    Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29723.
    PubMed     Text format     Abstract available


  33. BARI K, Luckett K, Kaiser T, Diwan T, et al
    Hepatitis C Transmission from Seropositive, Non-Viremic Donors to Non-Hepatitis C Liver Transplant Recipients.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29704.
    PubMed     Text format     Abstract available


  34. LI DK, Ren Y, Fierer DS, Rutledge S, et al
    The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29707.
    PubMed     Text format     Abstract available


  35. SORIA A, Lapadula G, Fabbiani M, Gori A, et al
    Lower effectiveness of hepatitis C antiviral treatment in patients with hepatocellular carcinoma: Is active tumor the clue?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29700.
    PubMed     Text format    


  36. JI F, Yeo YH, Wei MT, Wei B, et al
    Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29701.
    PubMed     Text format    


  37. HARRINGTON PR, Komatsu TE, Deming DJ, Donaldson EF, et al
    Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29693.
    PubMed     Text format     Abstract available


    November 2017
  38. SAAB S, Le L, Saggi S, Sundaram V, et al
    Towards the Elimination of Hepatitis C in the United States.
    Hepatology. 2017 Nov 27. doi: 10.1002/hep.29685.
    PubMed     Text format     Abstract available


  39. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    PubMed     Text format    


  40. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    PubMed     Text format    


  41. POORDAD F, Pol S, Asatryan A, Buti M, et al
    Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671.
    PubMed     Text format     Abstract available


  42. KALAL C, Shukla A, Mohanka R, Vora M, et al
    Sofosbuvir, Peg Interferon & Ribavirin for retreatment of HCV genotype 1b following Sofosbuvir and Ledipasvir failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29667.
    PubMed     Text format    


  43. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    PubMed     Text format    


  44. SIKAVI C, Chen PH, Lee AD, Saab EG, et al
    Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29642.
    PubMed     Text format     Abstract available


    October 2017
  45. LIU J
    Hepatitis B reactivation in chronic hepatitis C patients treated with interferon or pan-oral direct-acting antivirals.
    Hepatology. 2017 Oct 28. doi: 10.1002/hep.29620.
    PubMed     Text format    


  46. STRUBLE K, Chan-Tack K, Qi K, Naeger LK, et al
    Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV genotype: FDA's Evaluation.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29601.
    PubMed     Text format     Abstract available


  47. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611.
    PubMed     Text format     Abstract available


  48. YOUNOSSI ZM
    The Efficacy of New Anti-Viral Regimens for Hepatitis C Infection: Evidence from A Systematic Review.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29580.
    PubMed     Text format    


  49. GONZALEZ SA, Trotter JF
    The Rise of the Opioid Epidemic and Hepatitis C Positive Organs: A New Era in Liver Transplantation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29572.
    PubMed     Text format     Abstract available


    September 2017
  50. MAUGE L, Pavie J, Batisse D, Darnige L, et al
    Acquired hemophilia A resolution in an HCV/HIV coinfected patient with cure of hepatitis C by direct antiviral agents.
    Hepatology. 2017 Sep 28. doi: 10.1002/hep.29560.
    PubMed     Text format    


  51. CHTIOUI H
    OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29556.
    PubMed     Text format    


  52. AHMED A, Beckerman R, Younossi ZM
    Equitable Access to All-Oral Direct-Acting Antiviral Therapy is a Mandatory Step to Achieve Global Hepatitis C Virus Eradication.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29555.
    PubMed     Text format    


  53. MAURO E, Crespo G, Montironi C, Londono MC, et al
    Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29557.
    PubMed     Text format     Abstract available


  54. LIU X, Elmofti Y, Kulaga C, Gisi B, et al
    Societal perspectives' analysis for evaluating direct-acting antivirals affordability while awaiting liver transplant.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29558.
    PubMed     Text format    


  55. YARTEL AK, Rein DB, Ann Brown K, Krauskopf K, et al
    Hepatitis C Virus Testing for Case Identification in Persons Born during 1945-1965: Results from Three Randomized Controlled Trials.
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29548.
    PubMed     Text format     Abstract available


  56. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Text format     Abstract available


  57. VIONNET J, Pascual M, Testoni B, Combet C, et al
    Late hepatitis B reactivation following DAA-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29528.
    PubMed     Text format    


  58. LEE MH, Huang YH, Chen HY, Khor CS, et al
    Human Leukocyte Antigen Variants and Risk of Hepatocellular Carcinoma Modified by HCV Genotypes: A Genome-wide Association Study.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29531.
    PubMed     Text format     Abstract available


  59. PARK H, Chen C, Wang W, Henry L, et al
    Chronic Hepatitis C Increases the Risk of Chronic Kidney Disease (CKD) while Effective HCV Treatment Decreases the Incidence of CKD.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29505.
    PubMed     Text format     Abstract available


  60. TOYODA H, Chayama K, Suzuki F, Sato K, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.
    Hepatology. 2017 Sep 2. doi: 10.1002/hep.29510.
    PubMed     Text format     Abstract available


    August 2017
  61. TRIVEDI S, Murthy S, Sharma H, Hartlage AS, et al
    Viral persistence, liver disease and host response in Hepatitis C-like virus rat model.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29494.
    PubMed     Text format     Abstract available


  62. MATTINGLY TJ 2ND, Perfetto EM, Johnson S
    Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29482.
    PubMed     Text format     Abstract available


  63. INNES H, McAuley A, Alavi M, Valerio H, et al
    The contribution of health risk behaviours to excess mortality in American adults with chronic hepatitis C: A population cohort-study.
    Hepatology. 2017 Aug 4. doi: 10.1002/hep.29419.
    PubMed     Text format     Abstract available


  64. KRISS M, Burchill M
    HCV and non-hepatic malignancy: Is pre-emptive DAA therapy indicated prior to treatment?
    Hepatology. 2017 Aug 2. doi: 10.1002/hep.29414.
    PubMed     Text format    


    July 2017
  65. COBB DA, Golden-Mason L, Rosen HR, Hahn YS, et al
    Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during HCV infection.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29409.
    PubMed     Text format     Abstract available


  66. KONDILI LA, Romano F, Rolli FR, Ruggeri M, et al
    Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29399.
    PubMed     Text format     Abstract available


  67. KONERMAN MA, Thomson M, Gray K, Moore M, et al
    Impact of an Electronic Health Record Alert in Primary Care on Increasing Hepatitis C Screening and Curative Treatment for Baby Boomers.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29362.
    PubMed     Text format     Abstract available


  68. PERSICO M, Aglitti A, Caruso R, De Renzo A, et al
    Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29364.
    PubMed     Text format     Abstract available


  69. ROSEN HR, Ghany M, Chung R, Lok A, et al
    NAM 2017 Report: A National Plan To Eliminate Hepatitis B and C In the United States By 2030 And The AASLD's Response.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29361.
    PubMed     Text format    


  70. LOK AS, Chung RT, Vargas HE, Kim AY, et al
    Comments on Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Hepatology. 2017 Jul 16. doi: 10.1002/hep.29366.
    PubMed     Text format    


  71. WYLES D, Wedemeyer H, Ben-Ari Z, Gane EJ, et al
    Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.
    Hepatology. 2017 Jul 7. doi: 10.1002/hep.29358.
    PubMed     Text format     Abstract available


    June 2017
  72. SASAKI R, Devhare P, Ray RB, Ray R, et al
    Hepatitis C virus induced tumor initiating cancer stem-like cells activate stromal fibroblasts in xenograft tumor model.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29346.
    PubMed     Text format     Abstract available


  73. TORRES HA, Hosry J, Mahale P, Economides MP, et al
    Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29344.
    PubMed     Text format     Abstract available


  74. SISE M
    Kidney transplant recipients with Hepatitis C virus experienced 100% SVR12 rate when treated with sofosbuvir-ledipasvir.
    Hepatology. 2017 Jun 26. doi: 10.1002/hep.29339.
    PubMed     Text format    


  75. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    PubMed     Text format     Abstract available


  76. FALADE-NWULIA O, Sutcliffe C, Moon J, Chander G, et al
    High Hepatitis C cure rates among black and non-black HIV-infected adults in an urban center.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29308.
    PubMed     Text format     Abstract available


  77. CHHATWAL J, Samur S, Bethea E, Chung RT, et al
    Response to Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29299.
    PubMed     Text format    


  78. CHOLANKERIL G, Wong RJ, Kim D, Ahmed A, et al
    Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29300.
    PubMed     Text format    


    May 2017
  79. WIRTH S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, et al
    Sofosbuvir and Ribavirin in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29278.
    PubMed     Text format     Abstract available


  80. SAXENA V, Khungar V, Verna EC, Levitsky J, et al
    Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study.
    Hepatology. 2017 May 15. doi: 10.1002/hep.29258.
    PubMed     Text format     Abstract available


  81. GANE EJ, Shiffman ML, Etzkorn K, Morelli G, et al
    Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29256.
    PubMed     Text format     Abstract available


    April 2017
  82. PEMBROKE T, Sebastiani G
    Hepatic steatosis, hepatitis C and human immunodeficiency viruses: A complex interplay.
    Hepatology. 2017 Apr 19. doi: 10.1002/hep.29218.
    PubMed     Text format    


  83. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    PubMed     Text format     Abstract available


  84. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed     Text format    


  85. MERLI M, Frigeni M, Gotti M, Grossi P, et al
    Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas.
    Hepatology. 2017 Apr 5. doi: 10.1002/hep.29198.
    PubMed     Text format    


  86. LAI TS, Lee MH, Yang HI, You SL, et al
    Hepatitis C Viral Load, Genotype, and Increased Risk of Developing End-stage Renal Disease: REVEAL-HCV Study.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29192.
    PubMed     Text format     Abstract available


    March 2017
  87. PERRILLO RP
    HBV Reactivation During DAA Treatment of Chronic Hepatitis C: A Hidden Danger of an Otherwise Major Success Story.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29185.
    PubMed     Text format    


  88. SORIA A, Fabbiani M, Lapadula G, Gori A, et al
    Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181.
    PubMed     Text format    


  89. KIM SJ, Jang JY, Kim EJ, Cho EK, et al
    Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation.
    Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177.
    PubMed     Text format     Abstract available


  90. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  91. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed     Text format    


  92. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    PubMed     Text format     Abstract available


  93. STELMA F, van der Ree MH, Sinnige MJ, Brown A, et al
    Immune phenotype and function of NK and T cells in chronic hepatitis C patients who received a single dose of anti-miR-122, RG-101.
    Hepatology. 2017 Mar 11. doi: 10.1002/hep.29148.
    PubMed     Text format     Abstract available


  94. HEZODE C, Colombo M, Bourliere M, Spengler U, et al
    Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29139.
    PubMed     Text format     Abstract available


  95. AHMED A, Gonzalez SA, Cholankeril G, Perumpail RB, et al
    Treatment of Patients Waitlisted for Liver Transplant with an All-Oral DAAs is a Cost-Effective Treatment Strategy in the United States.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29137.
    PubMed     Text format     Abstract available


    February 2017
  96. BELPERIO PS, Shahoumian TA, Mole LA, Backus LI, et al
    Evaluation of Hepatitis B Reactivation among 62,920 Veterans treated with Oral Hepatitis C Antivirals.
    Hepatology. 2017 Feb 27. doi: 10.1002/hep.29135.
    PubMed     Text format     Abstract available


  97. YAN F, Wang Y, Zhang W, Chang M, et al
    Human ES Cell-derived Hepatoblasts are an Optimal Lineage Stage for HCV Infection.
    Hepatology. 2017 Feb 25. doi: 10.1002/hep.29134.
    PubMed     Text format     Abstract available


  98. LAWITZ E, Poordad F, Wells J, Hyland RH, et al
    Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130.
    PubMed     Text format     Abstract available


  99. HOGAN JJ, Lim MA, Palmer MB, Bloom RD, et al
    Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1).
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29125.
    PubMed     Text format     Abstract available


  100. SABERI B, Dadabhai AS, Durand CM, Philosophe B, et al
    Challenges in Treatment of Hepatitis C among Patients with Hepatocellular Carcinoma.
    Hepatology. 2017 Feb 17. doi: 10.1002/hep.29126.
    PubMed     Text format    


  101. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    PubMed     Text format     Abstract available


  102. CHEN G, Wang C, Chen J, Ji D, et al
    Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29109.
    PubMed     Text format     Abstract available


  103. DENOLLY S, Cosset FL
    A master regulator of tight junctions involved in hepatitis C virus entry and pathogenesis.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29066.
    PubMed     Text format    


  104. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Text format     Abstract available


  105. CARTER L, Aronsohn A
    Overcoming Injustice: A Roadmap to Improve Access to HCV Therapy for Our Medicaid Patients.
    Hepatology. 2017 Feb 4. doi: 10.1002/hep.29095.
    PubMed     Text format    


  106. OLIVEIRA C, Fournier C, Descamps V, Morel V, et al
    Apolipoprotein(a) Inhibits Hepatitis C Virus Entry Through Interaction With Infectious Particles.
    Hepatology. 2017 Feb 2. doi: 10.1002/hep.29096.
    PubMed     Text format     Abstract available


  107. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    PubMed     Text format     Abstract available


    January 2017
  108. POORDAD F, Felizarta F, Asatryan A, Sulkowski MS, et al
    Glecaprevir and Pibrentasvir for 12 Weeks for HCV Genotype 1 Infection and Prior Direct-acting Antiviral Treatment.
    Hepatology. 2017 Jan 27. doi: 10.1002/hep.29081.
    PubMed     Text format     Abstract available


  109. BERENGUER J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, et al
    Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29071.
    PubMed     Text format     Abstract available


  110. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Reply to "Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs".
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29069.
    PubMed     Text format    


  111. SMITH J, Rich J
    Addressing opioid use disorder in modeling hepatitis C transmission among persons who inject drugs.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29070.
    PubMed     Text format    


  112. O'BRIEN TR, Kottilil S, Feld JJ, Morgan TR, et al
    Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29057.
    PubMed     Text format    


  113. SU F, Ioannou GN
    Reply to: Race or Genetic Makeup for HCV Treatment Decisions?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29058.
    PubMed     Text format    


  114. VERNA EC
    The Dynamic Landscape of Liver Transplant in the Era of Effective HCV Therapy.
    Hepatology. 2017 Jan 17. doi: 10.1002/hep.29054.
    PubMed     Text format    


  115. ARORA P, Basu A, Schmidt ML, Clark GJ, et al
    NS5B Promotes Degradation of the NORE1A Tumor Suppressor to Facilitate Hepatitis C Virus Replication.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29049.
    PubMed     Text format     Abstract available


  116. HEI L, Zhong J
    LGP2 plays an essential role in HCV infection-induced interferon responses.
    Hepatology. 2017 Jan 16. doi: 10.1002/hep.29050.
    PubMed     Text format     Abstract available


    December 2016
  117. KOWDLEY KV, Sundaram V, Jeon CY, Qureshi K, et al
    Eight weeks of Ledipasvir/Sofosbuvir is effective for selected patients with genotype 1 Hepatitis C virus infection.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29005.
    PubMed     Text format     Abstract available


  118. VIETHEER P, Boo I, Gu J, McCaffrey K, et al
    The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28989.
    PubMed     Text format     Abstract available


  119. BALISTRERI WF, Murray KF, Rosenthal P, Bansal S, et al
    The Safety and Effectiveness of Ledipasvir-Sofosbuvir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 1 Infection.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28995.
    PubMed     Text format     Abstract available


  120. MARTINI S, Salizzoni M, David E, Tandoi F, et al
    Favorable short-term outcome of HCV-positive liver graft with bridging fibrosis: A plea for very early viral eradication.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28978.
    PubMed     Text format     Abstract available


  121. PRICE JC, Ma Y, Scherzer R, Korn N, et al
    HIV-infected and Uninfected Adults with Non-Genotype 3 Hepatitis C Virus Have Less Hepatic Steatosis than Adults with Neither Infection.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28968.
    PubMed     Text format     Abstract available


  122. ARTEMOVA M, Abdurakhmanov D, Ignatova T, Mukhin N, et al
    Persistent HCV-associated Cryoglobulinemic Vasculitis Following Virus Eradication after Direct-Acting Antivirals Therapy.
    Hepatology. 2016 Dec 10. doi: 10.1002/hep.28981.
    PubMed     Text format    


    November 2016
  123. LEVY PL, Duponchel S, Eischeid H, Molle J, et al
    Hepatitis C virus infection triggers a tumor-like glutamine metabolism.
    Hepatology. 2016 Nov 18. doi: 10.1002/hep.28949.
    PubMed     Text format     Abstract available


  124. CHHATWAL J, Samur S, Kues B, Ayer T, et al
    Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28926.
    PubMed     Text format     Abstract available


  125. NIU Y, Xu M, Slagle BL, Huang H, et al
    Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28924.
    PubMed     Text format     Abstract available


  126. FLEMMING JA, Kim WR, Brosgart CL, Terrault NA, et al
    Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28923.
    PubMed     Text format     Abstract available


    October 2016
  127. SU F, Green PK, Berry K, Ioannou GN, et al
    The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28901.
    PubMed     Text format     Abstract available


  128. LAWITZ E, Poordad F, Gutierrez JA, Wells JT, et al
    Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28877.
    PubMed     Text format     Abstract available


  129. BRADY JE, Liffmann DK, Yartel A, Kil N, et al
    Uptake of Hepatitis C Screening, Characteristics of Patients Tested, and Intervention Costs in the BEST-C Study.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28880.
    PubMed     Text format     Abstract available


  130. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed     Text format    


    September 2016
  131. KLEPPER A, Eng FJ, Doyle EH, El-Shamy A, et al
    Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28846.
    PubMed     Text format     Abstract available


  132. WANG RY, Bare P, De Giorgi V, Matsuura K, et al
    Preferential Association of Hepatitis C Virus with CD19+ B Cells Is Mediated by Complement System.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28842.
    PubMed     Text format     Abstract available


  133. KECK ZY, Wang Y, Lau P, Lund G, et al
    Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28850.
    PubMed     Text format     Abstract available


  134. ROSEN HR
    "Hep C, where art thou": What are the remaining (fundable) questions in HCV research?
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28848.
    PubMed     Text format    


  135. NISHIO A, Tatsumi T, Nawa T, Suda T, et al
    CD14+ monocyte-derived Galectin-9 induces NK cell cytotoxicity in chronic hepatitis C.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28847.
    PubMed     Text format     Abstract available


  136. MARTINELLO M, Gane E, Hellard M, Sasadeusz J, et al
    Sofosbuvir and ribavirin for six weeks is not effective among people with recent HCV infection: The DARE-C II study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28844.
    PubMed     Text format     Abstract available


  137. HILL LA, Wyles DL
    Emerging complexities with HCV DAA regimens: Less is still way more.
    Hepatology. 2016 Sep 16. doi: 10.1002/hep.28832.
    PubMed     Text format    


    August 2016
  138. DORE GJ
    Hepatitis C Treatment as Prevention among HIV-infected Men who have Sex with Men: Feasible?
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28784.
    PubMed     Text format    


  139. SALAZAR-VIZCAYA L, Kouyos RD, Zahnd C, Wandeler G, et al
    Hepatitis C virus transmission among HIV-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28769.
    PubMed     Text format     Abstract available


  140. TAWAR RG, Heydmann L, Bach C, Schuttrumpf J, et al
    Broad neutralization of hepatitis C virus resistant variants by Civacir(R) hepatitis C immune globulin.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28767.
    PubMed     Text format     Abstract available


  141. SALLOUM S, Holmes JA, Jindal R, Bale SS, et al
    HIV/HCV in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28766.
    PubMed     Text format     Abstract available


  142. BANKWITZ D, Pietschmann T
    Hepatitis C virus plays hide and seek with neutralizing antibodies.
    Hepatology. 2016 Aug 12. doi: 10.1002/hep.28760.
    PubMed     Text format    


  143. PAWLOTSKY JM
    The end of the hepatitis C burden: Really?
    Hepatology. 2016 Aug 3. doi: 10.1002/hep.28758.
    PubMed     Text format    


  144. GRAGNANI L, Visentini M, Fognani E, Urraro T, et al
    Prospective Study of Guideline-Tailored Therapy with Direct-Acting Antivirals for Hepatitis C Virus-Associated Mixed Cryoglobulinemia.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28753.
    PubMed     Text format     Abstract available


  145. ABE-CHAYAMA H, Hayes CN, Chayama K
    Pan-genotypic cell culture system for propagation of hepatitis c virus clinical isolates.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28751.
    PubMed     Text format    


    July 2016
  146. REGAN CP, Morissette P, Regan HK, Travis JJ, et al
    Preclinical Assessment of the Clinical Cardiac Drug-Drug Interaction Associated with the Combination of HCV-NI Antivirals and Amiodarone.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28752.
    PubMed     Text format     Abstract available


  147. SUGIYAMA M, Kanto T
    Dual blockade of HCV entry at a gatekeeper of hepatocytes - Not only a preventive but also therapeutic target of CLDN-1.
    Hepatology. 2016 Jul 12. doi: 10.1002/hep.28726.
    PubMed     Text format    


    June 2016
  148. ABERGEL A, Metivier S, Samuel D, Jiang D, et al
    Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28706.
    PubMed     Text format     Abstract available


  149. PRENTOE J, Velazquez-Moctezuma R, Foung SK, Law M, et al
    Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28705.
    PubMed     Text format     Abstract available


  150. GANNE-CARRIE N, Layese R, Bourcier V, Cagnot C, et al
    Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702.
    PubMed     Text format     Abstract available


  151. ULVELING D, Le Clerc S, Cobat A, Labib T, et al
    A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28695.
    PubMed     Text format     Abstract available


  152. HU KQ, Cui W
    A Highly Specific and Sensitive Hepatitis C Virus Antigens Enzyme Immunoassay for One-step Diagnosis of Viremic HCV Infection.
    Hepatology. 2016 Jun 6. doi: 10.1002/hep.28663.
    PubMed     Text format     Abstract available


    May 2016
  153. MATSUURA K, De Giorgi V, Schechterly C, Wang RY, et al
    Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28660.
    PubMed     Text format     Abstract available


  154. SCHREIBER J, McNally J, Chodavarapu K, Svarovskaia E, et al
    Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28636.
    PubMed     Text format    


  155. TOYODA H, Kumada T, Tada T
    Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.
    Hepatology. 2016 May 2. doi: 10.1002/hep.28632.
    PubMed     Text format    


    April 2016
  156. ASIMAKOPOULOS A, Mangia A, Dore GJ, Lloyd AR, et al
    Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans.
    Hepatology. 2016 Apr 27. doi: 10.1002/hep.28626.
    PubMed     Text format    


  157. HALFON P, Mohamed S, Penaranda G, Khiri H, et al
    Hepatitis c genotype 4r resistance associated polymorphisms: The achilles heel of the NS5A inhibitors?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28611.
    PubMed     Text format    


  158. VERLINDEN W, Francque S, Michielsen P, Vanwolleghem T, et al
    Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28610.
    PubMed     Text format    


  159. FOSCHI A, Casana M, Radice A, Ranieri R, et al
    CORRESPONDENCE: Hepatitis C management in prisons: An insight into daily clinical practice in three major Italian Correctional Houses.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28609.
    PubMed     Text format    


  160. BACKUS LI, Belperio PS, Shahoumian TA, Loomis TP, et al
    Real World Effectiveness of Ledipasvir/Sofosbuvir in 4365 Treatment-Naive Genotype 1 Hepatitis C Infected Patients.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28625.
    PubMed     Text format     Abstract available


  161. MARTIN NK, Vickerman P, Hickman M
    CORRESPONDENCE: HCV testing and treatment in Italian prisons: Implications for prevention benefit and cost-effectiveness.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28612.
    PubMed     Text format    


  162. OZARAS R, Sunbul M, Parlak M, Bodur H, et al
    Treating HBV/HCV Co-infected Patients with Direct Acting HCV Antivirals Only is not Safe.
    Hepatology. 2016 Apr 4. doi: 10.1002/hep.28592.
    PubMed     Text format    


  163. CUBERO FJ
    Shutting off inflammation: A novel switch on hepatic stellate cells.
    Hepatology. 2016;63:1086-9.
    PubMed     Text format    


  164. BARTNECK M, Fech V, Ehling J, Govaere O, et al
    Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.
    Hepatology. 2016;63:1310-24.
    PubMed     Text format     Abstract available


    March 2016
  165. PONZETTO A, Carloni G
    HCV and Lymphoma.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28580.
    PubMed     Text format    


  166. SU TH, Chen CL, Kao JH
    RE: HCV and Lymphoma.
    Hepatology. 2016 Mar 28. doi: 10.1002/hep.28578.
    PubMed     Text format    


  167. CHHATWAL J, Wang X, Ayer T, Kabiri M, et al
    Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28571.
    PubMed     Text format     Abstract available


  168. VARGAS H
    Hepatitis C Treatment In 2016: Reasons to be an OPTIMIST.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28559.
    PubMed     Text format    


  169. BUTI M, Sanchez-Ruano J, Morillas RM, Esteban R, et al
    Baseline HCV-RNA levels in genotype 1 Chronic Hepatitis C Patients: The role of different cut-off points.
    Hepatology. 2016 Mar 11. doi: 10.1002/hep.28544.
    PubMed     Text format    


  170. PEIFFER KH, Sommer L, Zeuzem S, Sarrazin C, et al
    Reply to the letter to the editor "Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a".
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28536.
    PubMed     Text format    


  171. EL-SERAG HB, Kanwal F, Richardson P, Kramer J, et al
    Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection.
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28535.
    PubMed     Text format     Abstract available


  172. PEDERGNANA V, Smith D, Klenerman P, Barnes E, et al
    Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a.
    Hepatology. 2016 Mar 4. doi: 10.1002/hep.28533.
    PubMed     Text format    


  173. HOFFMANN F, Endres S, Rothenfusser S
    Reply.
    Hepatology. 2016;63:1062-3.
    PubMed     Text format    


    February 2016
  174. SIMON TG, Bonilla H, Yan P, Chung RT, et al
    Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV Results from ERCHIVES.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28506.
    PubMed     Text format     Abstract available


  175. MARTIN NK, Vickerman P, Brew IF, Williamson J, et al
    Is increased HCV case-finding combined with current or 8-12 week DAA therapy cost-effective in UK prisons? A prevention benefit analysis.
    Hepatology. 2016 Feb 10. doi: 10.1002/hep.28497.
    PubMed     Text format     Abstract available


  176. LINDENBACH BD
    "What's next for hepatitis C virus research?"
    Hepatology. 2016 Feb 8. doi: 10.1002/hep.28494.
    PubMed     Text format    


  177. HEZODE C, Chevaliez S, Scoazec G, Soulier A, et al
    Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen.
    Hepatology. 2016 Feb 8. doi: 10.1002/hep.28491.
    PubMed     Text format     Abstract available


    January 2016
  178. LEROY V, Angus P, Bronowicki JP, Dore GJ, et al
    Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+).
    Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473.
    PubMed     Text format     Abstract available


  179. SACK J, Garcia-Tsao G
    Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28470.
    PubMed     Text format    


  180. KWO P, Gitlin N, Nahass R, Bernstein D, et al
    Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28467.
    PubMed     Text format     Abstract available


  181. INNES H, Hutchinson SJ, Obel N, Christensen PB, et al
    Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland - using spontaneous resolvers as the benchmark comparator.
    Hepatology. 2016 Jan 16. doi: 10.1002/hep.28458.
    PubMed     Text format     Abstract available


  182. DAHARI H, Cotler SJ, Feld JJ
    Cure prevents more than transmission of HCV.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28449.
    PubMed     Text format    


  183. POORDAD F, Schiff ER, Vierling JM, Landis C, et al
    Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446.
    PubMed     Text format     Abstract available


    December 2015
  184. DESOMBERE I, Fafi-Kremer S, Van Houtte F, Pessaux P, et al
    Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28428.
    PubMed     Text format     Abstract available


  185. REIN DB, Borton J, Liffmann DK, Wittenborn JS, et al
    The burden of hepatitis C to the United States medicare system in 2009: Descriptive and economic characteristics.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28430.
    PubMed     Text format     Abstract available


  186. SAAB S, Park SH, Mizokami M, Omata M, et al
    Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28425.
    PubMed     Text format     Abstract available


  187. LAWITZ E, Matusow G, DeJesus E, Yoshida EM, et al
    Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2).
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28422.
    PubMed     Text format     Abstract available


  188. GALMOZZI E
    Do ITPA gene variants provide insight to detecting patients infected with HCV 2/1 recombinant strains?
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28421.
    PubMed     Text format    


  189. WIELAND D, Thimme R
    Vaccine-induced HCV-specific CD8+ T cells do not always help.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28388.
    PubMed     Text format    


  190. SU TH, Liu CJ, Tseng TC, Chou SW, et al
    Hepatitis C virus infection increases the risk of lymphoid-neoplasms: A population-based cohort study.
    Hepatology. 2015 Dec 10. doi: 10.1002/hep.28387.
    PubMed     Text format     Abstract available


  191. CHO NE, Bang BR, Gurung P, Li M, et al
    Retinoid Regulation of Antiviral Innate Immunity in Hepatocytes.
    Hepatology. 2015 Dec 5. doi: 10.1002/hep.28380.
    PubMed     Text format     Abstract available


    November 2015
  192. PISCAGLIA F, Svegliati-Baroni G, Barchetti A, Pecorelli A, et al
    Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368.
    PubMed     Text format     Abstract available


  193. WILDER JM, Jeffers LJ, Ravendhran N, Shiffman ML, et al
    Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data.
    Hepatology. 2015 Nov 6. doi: 10.1002/hep.28334.
    PubMed     Text format     Abstract available


  194. HOPCRAFT SE, Evans MJ
    Liver Capsule: HCV Host Cell Entry.
    Hepatology. 2015 Nov 4. doi: 10.1002/hep.28329.
    PubMed     Text format    


  195. CHIDI AP, Rogal S, Bryce CL, Fine MJ, et al
    Cost-Effectiveness of New Antiviral Regimens for Treatment-Naive US Veterans with Hepatitis C.
    Hepatology. 2015 Nov 2. doi: 10.1002/hep.28327.
    PubMed     Text format     Abstract available


    October 2015
  196. BURZA MA, Motta BM, Mancina RM, Pingitore P, et al
    DEPDC5 variants increase fibrosis progression in Europeans with chronic HCV infection.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28322.
    PubMed     Text format     Abstract available


  197. CALLENDRET B, Eccleston HB, Satterfield W, Capone S, et al
    Persistent HCV replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and direct acting antiviral.
    Hepatology. 2015 Oct 29. doi: 10.1002/hep.28309.
    PubMed     Text format     Abstract available


  198. BRETT-MAJOR DM, Frick KD, Malia JA, Hakre S, et al
    Costs and consequences: Hepatitis C seroprevalance in the military and its impact on potential screening strategies.
    Hepatology. 2015 Oct 20. doi: 10.1002/hep.28303.
    PubMed     Text format     Abstract available


  199. SISE ME, Bloom AK, Wisocky J, Lin MV, et al
    Treatment of Hepatitis C Virus-Associated Mixed Cryoglobulinemia with Sofosbuvir-Based Direct-Acting Antiviral Agents.
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28297.
    PubMed     Text format     Abstract available


  200. KELLY C, Swadling L, Capone S, Brown A, et al
    Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28294.
    PubMed     Text format     Abstract available


  201. O'BRIEN TR, Feld JJ, Kottilil S, Pfeiffer RM, et al
    No Scientific Basis to Restrict 8 Weeks of Treatment with Ledipasvir/Sofosbuvir to Patients with HCV RNA <6,000,000 IU/ml.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28292.
    PubMed     Text format    


    September 2015
  202. COLSON P, Borentain P, Dhiver C, Benhaim S, et al
    Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France.
    Hepatology. 2015 Sep 29. doi: 10.1002/hep.28261.
    PubMed     Text format    


  203. PEIFFER KH, Sommer L, Susser S, Vermehren J, et al
    IFN lambda 4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients.
    Hepatology. 2015 Sep 25. doi: 10.1002/hep.28255.
    PubMed     Text format     Abstract available


  204. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28227.
    PubMed     Text format     Abstract available


  205. PRIGOZHIN DM, Modis Y
    Flunarizine Arrests Hepatitis C Virus Membrane Fusion.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28224.
    PubMed     Text format    


  206. CHUNG RT, Pearson S, Hur C
    Tackling the Hepatitis C Cost Problem: A Test Case for Tomorrow's Cures.
    Hepatology. 2015 Sep 11. doi: 10.1002/hep.28157.
    PubMed     Text format    


    August 2015
  207. SORIANO V, Barreiro P, de Mendoza C
    Hypoglycemia in a diabetic patient during hepatitis C therapy.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28137.
    PubMed     Text format    


  208. SIMON TG, Chung RT
    HEP-15-1079: The new HCV bottleneck: can delaying therapy be justified Reply to Letter to the Editor (LTE).
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28136.
    PubMed     Text format    


  209. CHIRIKOV VV, Shaya F, Mullins CD, dosReis S, et al
    Research is needed on the difficult-to-cure population of HCV patients with disability.
    Hepatology. 2015 Aug 11. doi: 10.1002/hep.28120.
    PubMed     Text format    


  210. KACHKO A, Frey SE, Sirota L, Ray R, et al
    Antibodies to an interfering epitope in hepatitis C Virus E2 can mask vaccine-induced neutralizing activity.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28108.
    PubMed     Text format     Abstract available


  211. WANG H, El Maadidi S, Fischer J, Grabski E, et al
    A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28105.
    PubMed     Text format     Abstract available


  212. TURNER B, Taylor B, Hanson J, Liang Y, et al
    High Priority for Hepatitis C Screening in Safety Net Hospitals: Results from a Prospective Cohort of 4582 Hospitalized Baby Boomers.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28018.
    PubMed     Text format     Abstract available


  213. FUJII Y, Uchida Y, Mochida S
    Reply to the Letter Entitled "Severe Hepatotoxicity Associated with Asunaprevir and Daclatasvir in Chronic Hepatitis C".
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28114.
    PubMed     Text format    


  214. SHIBATA S, Umemura T, Komatsu M, Tanaka E, et al
    Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis C.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28113.
    PubMed     Text format    


  215. PERIN PM, Haid S, Brown RJ, Doerrbecker J, et al
    Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28111.
    PubMed     Text format     Abstract available


  216. FUJITA T, Soontrapa K, Ito Y, Iwaisako K, et al
    Hepatic stellate cells relay inflammation signaling from sinusoids to parenchyma in mouse models of immune-mediated hepatitis.
    Hepatology. 2015 Aug 6. doi: 10.1002/hep.28112.
    PubMed     Text format     Abstract available


  217. RICE C, Chen Z
    Repurposing an old drug: A low-cost allergy medication provides new hope for hepatitis C patients.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28028.
    PubMed     Text format    


  218. KANNINEN TT, Dieterich D, Asciutti S
    HCV vertical transmission in pregnancy: New horizons in the era of DAAs.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28032.
    PubMed     Text format     Abstract available


  219. GISH RG, Cohen CA, Block JM, Brosgart CL, et al
    Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28026.
    PubMed     Text format    


    July 2015
  220. EDLIN BR, Eckhardt BJ, Shu MA, Holmberg SD, et al
    Towards a more accurate estimate of the prevalence of hepatitis C in the United States.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27978.
    PubMed     Text format     Abstract available


  221. KUMADA H, Chayama K, Rodrigues-Jr L, Suzuki F, et al
    Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir for HCV Genotype 1b-infected Japanese Patients With or Without Cirrhosis.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27972.
    PubMed     Text format     Abstract available


  222. CARLIN AF, Aristizabal P, Song Q, Wang H, et al
    Temporal dynamics of inflammatory cytokines/chemokines during Sofosbuvir and Ribavirin therapy for Genotype 2 and 3 Hepatitis C infection.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27971.
    PubMed     Text format     Abstract available


  223. DE MARTEL C, Maucort-Boulch D, Plummer M, Franceschi S, et al
    Worldwide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27969.
    PubMed     Text format     Abstract available


    June 2015
  224. CHAPKO MK, Dufour DR, Hatia R, Drobeniuc J, et al
    Cost-effectiveness of strategies for testing current hepatitis C virus infection.
    Hepatology. 2015 Jun 30. doi: 10.1002/hep.27966.
    PubMed     Text format     Abstract available


  225. PAWLOTSKY JM, Flisiak R, Sarin SK, Rasenack J, et al
    Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection.
    Hepatology. 2015 Jun 27. doi: 10.1002/hep.27960.
    PubMed     Text format     Abstract available



  226. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27950.
    PubMed     Text format    


  227. VERGARA C, Thio CL, Thomas D, Duggal P, et al
    Polymorphisms In Melanoma Differentiation-Associated Gene 5 Are Not Associated With Clearance Of Hepatitis C Virus In A European American Population.
    Hepatology. 2015 Jun 23. doi: 10.1002/hep.27954.
    PubMed     Text format    


  228. PEDERGNANA V, Abdel-Hamid M, Guergnon J, Theodorou I, et al
    Refined association of MDA5 variants with spontaneous hepatitis C virus clearance in Egypt.
    Hepatology. 2015 Jun 23. doi: 10.1002/hep.27951.
    PubMed     Text format    


  229. SHLOMAI A
    Hepatitis C virus addiction to liver miR-122 takes its toll on the host.
    Hepatology. 2015 Jun 19. doi: 10.1002/hep.27947.
    PubMed     Text format    


  230. AQEL B, Pungpapong S, Leise M, Werner KT, et al
    Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Hepatology. 2015 Jun 11. doi: 10.1002/hep.27937.
    PubMed     Text format     Abstract available


  231. LONTOK E, Harrington P, Howe A, Kieffer T, et al
    Hepatitis C Virus Drug Resistance-associated Substitutions: State of the Art Summary.
    Hepatology. 2015 Jun 10. doi: 10.1002/hep.27934.
    PubMed     Text format     Abstract available


  232. SIMON TG, Chung RT
    The new HCV bottleneck: Can delaying therapy be justified?
    Hepatology. 2015 Jun 8. doi: 10.1002/hep.27931.
    PubMed     Text format    


  233. SAXENA V, Nyberg L, Pauly M, Dasgupta A, et al
    Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C Infected Patients with Compensated and Decompensated Cirrhosis.
    Hepatology. 2015 Jun 1. doi: 10.1002/hep.27922.
    PubMed     Text format     Abstract available


  234. YOUNOSSI ZM, Stepanova M, Marcellin P, Afdhal N, et al
    Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Hepatology. 2015;61:1798-808.
    PubMed     Text format     Abstract available


    May 2015
  235. DICK TB, Lindberg LS, Ramirez DD, Charlton MR, et al
    A Clinician's Guide to Drug-Drug Interactions with Direct Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection.
    Hepatology. 2015 May 29. doi: 10.1002/hep.27920.
    PubMed     Text format     Abstract available


  236. TAWAR RG, Colpitts CC, Timm J, Fehm T, et al
    Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.
    Hepatology. 2015 May 23. doi: 10.1002/hep.27906.
    PubMed     Text format     Abstract available


  237. KUSUMA A, Romero-Brey I, Berger C, Colpitts CC, et al
    Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication via blockage of membranous web formation.
    Hepatology. 2015 May 22. doi: 10.1002/hep.27913.
    PubMed     Text format     Abstract available


  238. LIU Z, Chen T, Wang Y, Zhang M, et al
    Age might confound the impact of the TM6SF2 E167K polymorphism on hepatic fibrosis in HCV- infected patients.
    Hepatology. 2015 May 16. doi: 10.1002/hep.27899.
    PubMed     Text format    


  239. ROMEO S, Aghemo A, Berg T, Stickel F, et al
    TM6SF2 E167K and liver fibrosis in chronic hepatitis C.
    Hepatology. 2015 May 16. doi: 10.1002/hep.27901.
    PubMed     Text format    


  240. CECCHERINI SILBERSTEIN F, Di Maio VC, Aragri M, Ciotti M, et al
    Hepatitis C Virus Gene Sequencing as a Tool for Precise Genotyping in the Era of New Direct Antiviral Agents.
    Hepatology. 2015 May 14. doi: 10.1002/hep.27895.
    PubMed     Text format    


  241. TERRAULT N
    Difficult-to-Cure populations with chronic hepatitis C: Vanishing in the DAA era?
    Hepatology. 2015 May 12. doi: 10.1002/hep.27892.
    PubMed     Text format    


  242. ALQAHTANI SA, Afdhal N, Zeuzem S, Gordon S, et al
    Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27890.
    PubMed     Text format     Abstract available


  243. YOUNOSSI ZM, Jiang Y, Smith NJ, Stepanova M, et al
    Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
    Hepatology. 2015;61:1471-8.
    PubMed     Text format     Abstract available


    April 2015
  244. ABDELRAHMAN T, Hughes J, Main J, McLauchlan J, et al
    Reply.
    Hepatology. 2015;61:1438.
    PubMed     Text format    


    February 2015
  245. TRINCHET JC, Bourcier V, Chaffaut C, Ait Ahmed M, et al
    Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27743.
    PubMed     Text format     Abstract available


    October 2014
  246. MULLER T, Wiese M, Berg T
    Reply: To PMID 23929603.
    Hepatology. 2014;60:1449-50.
    PubMed     Text format    


  247. MONDELLI MU
    The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
    Hepatology. 2014;60:1126-9.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: